These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 11017150)

  • 1. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.
    Bielekova B; Goodwin B; Richert N; Cortese I; Kondo T; Afshar G; Gran B; Eaton J; Antel J; Frank JA; McFarland HF; Martin R
    Nat Med; 2000 Oct; 6(10):1167-75. PubMed ID: 11017150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MBP-8298, a synthetic peptide analog of myelin basic protein for the treatment of multiple sclerosis.
    Darlington C
    Curr Opin Mol Ther; 2007 Aug; 9(4):398-402. PubMed ID: 17694453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.
    Bar-Or A; Vollmer T; Antel J; Arnold DL; Bodner CA; Campagnolo D; Gianettoni J; Jalili F; Kachuck N; Lapierre Y; Niino M; Oger J; Price M; Rhodes S; Robinson WH; Shi FD; Utz PJ; Valone F; Weiner L; Steinman L; Garren H
    Arch Neurol; 2007 Oct; 64(10):1407-15. PubMed ID: 17698695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides.
    Fontoura P; Garren H; Steinman L
    Int Rev Immunol; 2005; 24(5-6):415-46. PubMed ID: 16318989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-reactivity of T-cell clones specific for altered peptide ligands of myelin basic protein.
    Ausubel LJ; Bieganowska KD; Hafler DA
    Cell Immunol; 1999 Apr; 193(1):99-107. PubMed ID: 10202117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific immunotherapy: one size does not fit all.
    Genain CP; Zamvil SS
    Nat Med; 2000 Oct; 6(10):1098-100. PubMed ID: 11017135
    [No Abstract]   [Full Text] [Related]  

  • 7. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group.
    Kappos L; Comi G; Panitch H; Oger J; Antel J; Conlon P; Steinman L
    Nat Med; 2000 Oct; 6(10):1176-82. PubMed ID: 11017151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A putative bioactive conformation for the altered peptide ligand of myelin basic protein and inhibitor of experimental autoimmune encephalomyelitis [Arg91, Ala96] MBP87-99.
    Mantzourani ED; Tselios TV; Grdadolnik SG; Brancale A; Platts JA; Matsoukas JM; Mavromoustakos TM
    J Mol Graph Model; 2006 Sep; 25(1):17-29. PubMed ID: 16310386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of gender on T-cell proliferative responses to myelin proteolipid protein antigens in patients with multiple sclerosis and controls.
    Greer JM; Csurhes PA; Pender MP; McCombe PA
    J Autoimmun; 2004 Jun; 22(4):345-52. PubMed ID: 15120759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of experimental autoimmune encephalomyelitis in Lewis rats by a viral peptide with limited homology to myelin basic protein.
    Mao YS; Lu CZ; Wang X; Xiao BG
    Exp Neurol; 2007 Aug; 206(2):231-9. PubMed ID: 17617406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mimicry and antigen-specific T cell responses in multiple sclerosis and chronic CNS Lyme disease.
    Martin R; Gran B; Zhao Y; Markovic-Plese S; Bielekova B; Marques A; Sung MH; Hemmer B; Simon R; McFarland HF; Pinilla C
    J Autoimmun; 2001 May; 16(3):187-92. PubMed ID: 11334482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis.
    Garren H; Robinson WH; Krasulová E; Havrdová E; Nadj C; Selmaj K; Losy J; Nadj I; Radue EW; Kidd BA; Gianettoni J; Tersini K; Utz PJ; Valone F; Steinman L;
    Ann Neurol; 2008 May; 63(5):611-20. PubMed ID: 18481290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood CD8+ T cell responses against myelin determinants in multiple sclerosis and healthy individuals.
    Berthelot L; Laplaud DA; Pettré S; Ballet C; Michel L; Hillion S; Braudeau C; Connan F; Lefrère F; Wiertlewski S; Guillet JG; Brouard S; Choppin J; Soulillou JP
    Eur J Immunol; 2008 Jul; 38(7):1889-99. PubMed ID: 18506883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of novel cyclic altered peptide ligands of myelin basic protein MBP83-99 that modulate immune responses in SJL/J mice.
    Katsara M; Deraos G; Tselios T; Matsoukas J; Apostolopoulos V
    J Med Chem; 2008 Jul; 51(13):3971-8. PubMed ID: 18563891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-reactivity with myelin basic protein and human herpesvirus-6 in multiple sclerosis.
    Tejada-Simon MV; Zang YC; Hong J; Rivera VM; Zhang JZ
    Ann Neurol; 2003 Feb; 53(2):189-97. PubMed ID: 12557285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular dynamics at the receptor level of immunodominant myelin basic protein epitope 87-99 implicated in multiple sclerosis and its antagonists altered peptide ligands: triggering of immune response.
    Mantzourani ED; Platts JA; Brancale A; Mavromoustakos TM; Tselios TV
    J Mol Graph Model; 2007 Sep; 26(2):471-81. PubMed ID: 17392002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of a cyclic double mutant peptide (cyclo(87-99)[A91,A96]MBP87-99) induces altered responses in mice after conjugation to mannan: implications in the immunotherapy of multiple sclerosis.
    Katsara M; Deraos G; Tselios T; Matsoukas MT; Friligou I; Matsoukas J; Apostolopoulos V
    J Med Chem; 2009 Jan; 52(1):214-8. PubMed ID: 19072222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroimmunology of multiple sclerosis and experimental allergic encephalomyelitis.
    Stuerzebecher S; Martin R
    Neuroimaging Clin N Am; 2000 Nov; 10(4):649-68 ,vii-viii. PubMed ID: 11359717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis of molecular mimicry.
    Wucherpfennig KW
    J Autoimmun; 2001 May; 16(3):293-302. PubMed ID: 11334495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for the binding of an immunodominant peptide from myelin basic protein in different registers by two HLA-DR2 proteins.
    Li Y; Li H; Martin R; Mariuzza RA
    J Mol Biol; 2000 Nov; 304(2):177-88. PubMed ID: 11080454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.